Efficacy Analysis of Suprapapillary versus Transpapillary Self-Expandable Metal Stents According to the Level of Obstruction in Malignant Extrahepatic Biliary Obstruction
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The use of a self-expandable metal stent (SEMS) is recommended for unresectable malignant biliary obstruction (MBO). Stent-related adverse events might differ according to the position of the stent through the ampulla of Vater (AOV). We retrospectively evaluated SEMS patency and adverse events according to the position of the SEMS. Methods: In total, 280 patients who underwent endoscopic SEMS placement due to malignant distal biliary obstruction were analyzed retrospectively. Suprapapillary and transpapillary SEMS insertions were performed on 51 patients and 229 patients, respectively. Results: Between the suprapapillary group (SPG) and transpapillary group (TPG), the stent patency period was not significantly different (median [95% confidence interval]: 107 days [82.3 to 131.7] vs 120 days [99.3 to 140.7], p=0.559). There was also no significant difference in the rate of adverse events. In subgroup analysis, the stent patency for an MBO located within 2 cm from the AOV was found to be significantly shorter than that for an MBO located more than 2 cm from the AOV in the SPG (64 days [0 to 160.4] vs 127 days [82.0 to 171.9], p<0.001) and TPG (87 days [52.5 to 121.5] vs 130 [97.0 to 162.9], p<0.001). Patients with an MBO located within 2 cm from the AOV in both groups had a higher percentage of duodenal invasion (SPG: 40.0% vs 4.9%, p=0.002; TPG: 28.6% vs 2.9%, p<0.001) than patients with an MBO located more than 2 cm from the AOV. Conclusions: The SPG and TPG showed similar results in terms of stent patency and rate of adverse events. However, patients with an MBO located within 2 cm from the AOV had a higher percentage of duodenal invasion with shorter stent patency than those with an MBO located more than 2 cm from the AOV, regardless of stent position.
Abstract
Background/Aims: The use of a self-expandable metal stent (SEMS) is recommended for unresectable malignant biliary obstruction (MBO). Stent-related adverse events might differ according to the position of the stent through the ampulla of Vater (AOV). We retrospectively evaluated SEMS patency and adverse events according to the position of the SEMS. Methods: In total, 280 patients who underwent endoscopic SEMS placement due to malignant distal biliary obstruction were analyzed retrospectively. Suprapapillary and transpapillary SEMS insertions were performed on 51 patients and 229 patients, respectively. Results: Between the suprapapillary group (SPG) and transpapillary group (TPG), the stent patency period was not significantly different (median [95% confidence interval]: 107 days [82.3 to 131.7] vs 120 days [99.3 to 140.7], p=0.559). There was also no significant difference in the rate of adverse events. In subgroup analysis, the stent patency for an MBO located within 2 cm from the AOV was found to be significantly shorter than that for an MBO located more than 2 cm from the AOV in the SPG (64 days [0 to 160.4] vs 127 days [82.0 to 171.9], p<0.001) and TPG (87 days [52.5 to 121.5] vs 130 [97.0 to 162.9], p<0.001). Patients with an MBO located within 2 cm from the AOV in both groups had a higher percentage of duodenal invasion (SPG: 40.0% vs 4.9%, p=0.002; TPG: 28.6% vs 2.9%, p<0.001) than patients with an MBO located more than 2 cm from the AOV. Conclusions: The SPG and TPG showed similar results in terms of stent patency and rate of adverse events. However, patients with an MBO located within 2 cm from the AOV had a higher percentage of duodenal invasion with shorter stent patency than those with an MBO located more than 2 cm from the AOV, regardless of stent position.
참고문헌 (23)
- Leng JJ, "Percutaneous transhepatic and endoscopic biliary drainage for malignant biliary tract obstruction : a meta-analysis", World J Surg Oncol, 12, pp.272~ (2014)
- Takenaka Mamoru, "Endoscopic Reintervention for Recurrence of Malignant Biliary Obstruction: Developing the Best Strategy", Gut and Liver, 16(4), pp.525~534 (2022), 거트앤리버 소화기연관학회협의회[DOI]
- Barkun AN, "Partially covered self-expandable metal stents versus polyethylene stents for malignant biliary obstruction : a cost-effectiveness analysis", Can J Gastroenterol Hepatol, 29, pp.377~383 (2015)
- Kuwatani M, "Possible reasons for the regrettable results of patency of an inside stent in endoscopic transpapillary biliary stenting", Dig Endosc, 34, pp.334~344 (2022)
- Paik WH, "EUS-guided biliary drainage versus ERCP for the primary palliation of malignant biliary obstruction : a multicenter randomized clinical trial", Am J Gastroenterol, 113, pp.987~997 (2018)
- Woo HY, "Role of endoscopic biliary drainage in advanced hepatocellular carcinoma with jaundice", PLoS One, 12, pp.e0187469~ (2017)
- Cotton PB, "Endoscopic sphincterotomy complications and their management : an attempt at consensus", Gastrointest Endosc, 37, pp.383~393 (1991)
- Kobayashi N, "Endoscopic inside stent placement is suitable as a bridging treatment for preoperative biliary tract cancer", BMC Gastroenterol, 15, pp.8~ (2015)
- Pécsi D, "Are suprapapillary biliary stents superior to transpapillary biliary stents?", Dig Dis Sci, 65, pp.925~927 (2020)
- Shin J, "Comparison of the clinical outcomes of suprapapillary and transpapillary stent insertion in unresectable cholangiocarcinoma with biliary obstruction", Dig Dis Sci, 65, pp.1231~1238 (2020)
- Pécsi D, "Suprapapillary biliary stent placement might have longer patency time compared to transpapillary stent placement : a systematic review and meta-analysis", Endoscopy, 50, pp.S43~ (2018)
- Walters JR, "A new mechanism for bile acid diarrhea : defective feedback inhibition of bile acid biosynthesis", Clin Gastroenterol Hepatol, 7, pp.1189~1194 (2009)
- Nam HS, "Efficacy and safety of limited endoscopic sphincterotomy before self-expandable metal stent insertion for malignant biliary obstruction", World J Gastroenterol, 23, pp.1627~1636 (2017)
- Shah A, "Increased rates of duodenal obstruction in pancreatic cancer patients receiving modern medical management", Dig Dis Sci, 59, pp.2294~2298 (2014)
- Patel BN, "Duodenal invasion by pancreatic adenocarcinoma: MDCT diagnosis of an aggressive imaging phenotype and its clinical implications", Abdom Radiol(NY), 43, pp.332~339 (2018)
- Ebata T, "Pancreatic and duodenal invasion in distal bile duct cancer : paradox in the tumor classification of the American Joint Committee on Cancer", World J Surg, 31, pp.2008~2015 (2007)
- Chen MY, "Covered stents versus uncovered stents for unresectable malignant biliary strictures : a meta-analysis", Biomed Res Int, 2016, pp.6408067~ (2016)
- Qin WY, "Covered and uncovered selfexpandable metallic stents in the treatment of malignant biliary obstruction", Iran Red Crescent Med J, 22, pp.e99928~ (2020)
- Conroy T, "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)
- Von Hoff DD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", N Engl J Med, 369, pp.1691~1703 (2013)
- Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer", N Engl J Med, 362, pp.1273~1281 (2010)
- Park CH, "Comparative efficacy of various stents for palliation in patients with malignant extrahepatic biliary obstruction : a systematic review and network meta-analysis", J Pers Med, 11, pp.86~ (2021)
- Saito Kei, "A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: BTS-NAC Study", Gut and Liver, 15(1), pp.135~141 (2021), 거트앤리버 소화기연관학회협의회[DOI]